ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema
(Thomson Reuters ONE) -
LEUVEN, Belgium, April 20, 2017 - ThromboGenics, a biotechnology company
focusing on novel treatments for back of the eye disease and diabetic eye
disease, announced it has achieved an important milestone in the advancing of
the pre-clinical development of its THR-149, a novel plasma kallikrein
inhibitor, which the company is developing for the treatment of Diabetic Macular
Edema (DME). Following today's announcement, ThromboGenics will now start
pivotal tox studies which are a last step before starting the clinical
development which is expected for early 2018.
THR-149 is a bicyclic peptide (Bicycle®) identified as a lead candidate in the
alliance between ThromboGenics and Bicycle Therapeutics, a biotechnology company
pioneering a new class of therapeutics based on its proprietary bicyclic peptide
(Bicycle®) product platform.
Under the terms of the alliance agreement, ThromboGenics has an exclusive
license to undertake pre-clinical and clinical development and subsequent
commercialization of a specified drug candidate; in return Bicycle Therapeutics
receives development milestone payments and royalties on sales of products
resulting from the collaboration.
Bicycles are a novel class of small molecule medicines designed to overcome many
of the limitations of existing drug modalities. They can be used as standalone
therapeutic entities or coupled to deliver a variety of therapeutic payloads,
and exhibit the affinity and exquisite target specificity usually associated
with antibodies but in a small molecule format enabling rapid tissue penetration
and flexible routes of administration.
"I am happy to report this important progress in our partnership with Bicycle
Therapeutics," said Dr. Patrik De Haes, MD, Chief Executive Officer of
ThromboGenics NV. "We believe that THR-149, a novel plasma kallikrein inhibitor,
holds great promise for ophthalmology applications, expanding the range of
treatment options available for people with diseases of the eye, particularly
DME. We are rapidly moving towards the clinic, and expect to begin clinical
development of THR-149 in early 2018."
"We're delighted to be realizing the first milestone from our Bicycle alliance
with ThromboGenics and to see another Bicycle to be advancing towards the clinic
for the treatment of a significant disease, in this case DME" said Dr. Kevin
Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "This achievement
further validates Bicycle's technology and confirms the potential for Bicycles
to be developed as a new therapeutic modality option to address a broad range of
poorly treated diseases. We are continuing to expand our pipeline through
strategic research collaborations which will extend our reach into new
therapeutic areas and allow us to explore new applications for the Bicycle
platform."
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on developing innovative
treatments for diabetic eye disease. The company's pipeline of disease modifying
drug candidates is targeting the key segments of the diabetic eye disease
market. ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial
evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior
Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy
(NPDR). Early 2017, ThromboGenics enrolled its first patient in a Phase II
clinical study evaluating THR- 317, a PIGF inhibitor for the treatment of
diabetic macular edema, as a stand-alone or as a combination therapy with anti-
VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has
resulted from research collaboration with Bicycle Therapeutics, and THR-687, an
integrin antagonist, which was inlicensed from Galapagos, are in late stage pre-
clinical development. ThromboGenics pioneered a new drug category of
pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for
the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics
is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US.
Novartis commercializes JETREA® outside the United States. ThromboGenics is
headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels
exchange under the symbol THR. More information is available at
www.thrombogenics.com.
About Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of medicines to treat oncology
and other important diseases based on its proprietary bicyclic peptide
(Bicycle(®)) product platform. Bicycles exhibit the affinity and exquisite
target specificity usually associated with antibodies. Their small size enables
rapid and deep tissue penetration, allowing tissues and tumours to be targeted
from within. Their peptidic nature provides a "tuneable" pharmacokinetic half-
life and a renal route of clearance, thus avoiding the liver and
gastrointestinal tract toxicity often seen with other drug modalities. Bicycle
Therapeutics is rapidly advancing towards the clinic with its lead programs
using Bicycle Drug Conjugates(®) to selectively deliver toxins to tumours.
Bicycle Therapeutics is collaborating in oncology and other areas to realise the
full potential of the technology. Bicycle Therapeutics' unique intellectual
property is based on the work initiated at the MRC Laboratory of Molecular
Biology in Cambridge, U.K., by the scientific founders of the company, Sir
Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is
headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge,
Massachusetts. For more information, visit www.bicycletherapeutics.com.
For contacting ThromboGenics nv
+------------------------------------+---------------------------------+
| | |
| | |
| ThromboGenics | Citigate Dewe Rogerson |
| | |
| Wouter Piepers, | David Dible/Sylvie Berrebi |
| | |
| wouter.piepers(at)thrombogenics.com | david.dible(at)citigatedr.co.uk |
| | |
| +32 16 75 13 10 / +32 478 33 56 32 | Sylvie.berrebi(at)citigatedr.co.uk |
| | |
| | Tel: +44 20 7282 2867 |
+------------------------------------+---------------------------------+
For contacting Bicycle Therapeutics
+---------------------------------+--------------------------------------------+
| | |
| | |
|Ten Bridge Communications (U.S.) |Consilium Strategic Communications (EU) |
|Sarah Sutton |Mary-Jane Elliott/ Chris Gardner/ Ivar |
|Sarah(at)tenbridgecommunications.com|Milligan |
| | |
|+1-857-242-1619 |Bicycle(at)consilium-comms.com |
| | |
| |+44 20 3709 5700 |
+---------------------------------+--------------------------------------------+
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ThromboGenics NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 537183
Anzahl Zeichen: 10432
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema"
steht unter der journalistisch-redaktionellen Verantwortung von
ThromboGenics NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
